

<b>DATE:</b>	2021 August 9
<b>TO:</b>	All Zones: Oncologists and Laboratory Services Personnel
<b>FROM:</b>	Alberta Precision Laboratories – Anatomical Pathology
<b>RE:</b>	<b>Implementation of the NEW Oncotype Dx™ Requisition and Supporting Documents</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- A **NEW** Provincial Oncotype Dx™ Requisition 21809 (2021-07) has been created to replace the previous breast molecular request form.
- Patient, provider and collection fragments have been expanded to include fields required to ensure appropriate handling, testing and reporting.
- All test criteria listed on the requisition must be met and surgical accession number must be provided by oncology personnel before testing can proceed.
- All Prosigna™ references and documents have been archived as it is no longer available in Alberta (as of July 23, 2020).
- Supporting documentation has been updated to accurately reflect the ordering of Oncotype Dx™.

### Background

- A new requisition has been created to simplify the request process and remove unnecessary information about Prosigna™. This requisition defines the eligible patient criteria for OncotypeDx™ testing.
- The new Oncotype Dx™ Requisition will include enhanced demographic fragments to support positive patient and sample identification and facilitate correct report delivery to clinicians.

### How this will impact you

Requisition	Ordering details
<b>NEW</b> – Oncotype Dx™ Requisition 21809 (2021-07) <a href="https://www.albertahealthservices.ca/fm-21809.pdf">https://www.albertahealthservices.ca/fm-21809.pdf</a>	<ul style="list-style-type: none"> <li>• Requisition is now available on the Alberta Precision Laboratories (APL) Website under <i>Requisitions</i>: <a href="https://www.albertaprecisionlabs.ca/hp/Page13849.aspx">https://www.albertaprecisionlabs.ca/hp/Page13849.aspx</a></li> <li>• Requisition to be completed for breast molecular testing samples as outlined by <i>PAPBRS21001MUL Oncotype Dx™ Molecular Breast Cancer Testing and Reporting – Oncologist</i></li> <li>• Surgical accession number <b>must</b> be provided to proceed with testing</li> </ul>

### Action Required

- Follow current ordering process to obtain an updated version of the Oncotype Dx™ Requisition 21809 (2021-07)
- Review the following documents for more information on the Oncotype Dx process:
  - “**PAPBRS21001MUL Oncotype Dx™ Molecular Breast Cancer Testing and Reporting – Oncologist**”: <https://ahs.labqms.com/labFrame.asp?DID=30711&FLDVr=1241>



- “PAPHIS21001MUL **Oncotype Dx™ Molecular Breast Cancer Testing and Reporting – Laboratory**”: <https://ahs.labqms.com/labFrame.asp?DID=21799&FLDVR=1241>
- Utilize current requisitions to ensure information aligns with required fields in Connect Care (CC). Information and identifiers such as **CC Provider ID** and **CC Submitter ID** are *vital for report routing*.

**Effective**      Immediately

**Questions/Concerns**

- Refer to your designated Biomarker Testing Laboratory

**Approved by**

- Dr. Christopher Walker, North Section Chief, Anatomical Pathology
- Dr. Ranjit Waghray, South Sector Chief, Anatomical Pathology